Allos Therapeutics to Host Analyst and Investor Briefing on Monday, December 8, 2008

  
    
  
  
    
      Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company 
      focused on developing and commercializing innovative small molecule 
      drugs for the treatment of cancer, today announced that it will host an 
      analyst and investor briefing in conjunction with the 50th 
      Annual Meeting of the American Society of Hematology (ASH) from 6:00 
      p.m. to 8:00 p.m. (Pacific) on Monday, December 8, 2008.
    
    
      Members of the Company’s senior management will provide a corporate 
      overview. In addition, key investigators from the Company’s pivotal 
      Phase 2 PROPEL trial in patients with relapsed or refractory peripheral 
      T-cell lymphoma will review top line results from the trial.
    
    
      The event will be webcast and may be accessed through a link posted on 
      the Allos website home page and investor relations section. The webcast 
      will be available for replay on Allos’ website through December 19, 2008.
    
    
      About Allos Therapeutics, Inc.
    
    
      Allos Therapeutics is a biopharmaceutical company focused on developing 
      and commercializing innovative small molecule drugs for the treatment of 
      cancer. The Company's lead product candidate, pralatrexate (PDX), is a 
      novel antifolate currently under evaluation in a pivotal Phase 2 
      (PROPEL) trial in patients with relapsed or refractory peripheral T-cell 
      lymphoma. The PROPEL trial is being conducted under an agreement reached 
      with the U.S. Food and Drug Administration under its special protocol 
      assessment, or SPA process. The Company is also investigating 
      pralatrexate in patients with non-small cell lung cancer, bladder cancer 
      and a range of lymphoma sub-types. The Company's other product 
      candidate is RH1, a targeted chemotherapeutic agent currently being 
      evaluated in a Phase 1 trial in patients with advanced solid tumors or 
      non-Hodgkin’s lymphoma (NHL). The Company currently retains exclusive 
      worldwide rights to pralatrexate and RH1 for all indications. For 
      additional information, please visit the Company’s website at www.allos.com.
    
    
      Safe Harbor Statement
    
    
      The anticipated presentation will contain forward-looking statements 
      that involve significant risks and uncertainties. Additional information 
      concerning these forward-looking statements and other factors that may 
      cause actual results to differ materially from those anticipated in the 
      forward-looking statements is contained in the "Risk Factors" section of 
      the Company's Annual Report on Form 10-K for the year ended December 31, 
      2007 and in the Company's other periodic reports and filings with the 
      Securities and Exchange Commission. The Company cautions investors not 
      to place undue reliance on the forward-looking statements contained in 
      the presentation. All forward-looking statements are based on 
      information currently available to the Company on the date thereof, and 
      the Company undertakes no obligation to revise or update these 
      forward-looking statements to reflect events or circumstances after the 
      date of this presentation, except as required by law.